Suppr超能文献

急性间歇性卟啉症的分子诊断

Molecular diagnostics of acute intermittent porphyria.

作者信息

Kauppinen Raili

机构信息

Department of Medicine, University Hospital of Helsinki, Biomedicum-Helsinki, BOX 700 00029 HUS, Helsinki, Finland.

出版信息

Expert Rev Mol Diagn. 2004 Mar;4(2):243-9. doi: 10.1586/14737159.4.2.243.

Abstract

Acute intermittent porphyria (AIP) is an inherited metabolic disease with an autosomal dominant pattern of inheritance. The disease is caused by a partial deficiency of porphobilinogen deaminase (PBGD) in heme biosynthesis. Since biochemical measurements of patients and their healthy relatives overlap, the diagnosis of AIP may remain undetermined at the symptom-free phase. Mutation detection in AIP, which provides 95% sensitivity and around 100% specificity, has quickly been incorporated into good clinical practice. During an acute attack, which includes various neurovisceral symptoms, measurement of urinary porphobilinogen (PBG) is a method of choice to confirm diagnosis, and DNA testing is unnecessary at that stage. DNA testing has revealed many new patients and excluded AIP from many healthy relatives despite slightly increased excretions of porphyrin precursors and erythrocyte PBGD in the low or borderline zone. Thus, quality-assured DNA testing is accurate enough to confirm or exclude the diagnosis of AIP. The clinical utility of DNA testing is limited for those individuals whose mutation is currently unknown, in which biochemical analyses are essential and the majority of the patients can be identified using urinary PBG and erythrocyte PBGD measurements. The measurement of urinary PBG can be used to evaluate the prognosis for symptom-free individuals. Currently, DNA testing of AIP at the population level is not recommended unless the frequency of gene carriers is locally very high and large-scale population-based mutation screening is reasonable. In the future, the knowledge of gene-gene and gene-environment interactions and protein networks using gene array and proteomics technologies may provide more precise information about pathogenetic mechanisms and novel therapeutic strategies for an acute attack and the long-term complications of AIP. Increasing knowledge of pharmacogenetics may identify the patients who are at high risk for clinical manifestations.

摘要

急性间歇性卟啉病(AIP)是一种具有常染色体显性遗传模式的遗传性代谢疾病。该疾病由血红素生物合成过程中胆色素原脱氨酶(PBGD)部分缺乏引起。由于患者及其健康亲属的生化检测结果存在重叠,AIP在无症状阶段的诊断可能无法确定。AIP的突变检测灵敏度达95%,特异性接近100%,已迅速融入良好的临床实践。在急性发作期间,患者会出现各种神经内脏症状,检测尿胆色素原(PBG)是确诊的首选方法,此阶段无需进行DNA检测。DNA检测发现了许多新患者,并排除了许多健康亲属患AIP的可能,尽管这些亲属的卟啉前体和红细胞PBGD排泄量略有增加,处于低水平或临界范围。因此,质量有保证的DNA检测足以准确确诊或排除AIP。对于那些目前未知突变的个体,DNA检测的临床效用有限,此时生化分析至关重要,大多数患者可通过检测尿PBG和红细胞PBGD来确诊。检测尿PBG可用于评估无症状个体的预后。目前,除非当地基因携带者的频率非常高且大规模基于人群的突变筛查合理,否则不建议在人群层面进行AIP的DNA检测。未来,利用基因芯片和蛋白质组学技术了解基因-基因和基因-环境相互作用以及蛋白质网络,可能会为AIP的发病机制、急性发作的新治疗策略以及长期并发症提供更精确的信息。药物遗传学知识的不断增加可能会识别出有临床表现高风险的患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验